舒尼替尼治疗非小细胞肺癌的现状
杨清杰;孙晓雁
【期刊名称】《中国肿瘤临床》 【年(卷),期】2011(038)015
【摘要】Sunitinib malate is one of the multi-targeted tyrosine kinase inhibitors in clinical use. It inhibits thc tyrosine kinase of over 80 receptors, including the receptors of epidermal growth factor, platelet-derived growth factor, and vascular endothelial growth factor. Since 2006, it has been successfully administered to treat advanced renal cell carcinoma and imatinib-resistant or intolerant gastrointestinal stromal tumors. In addition, the mutation and overcxpression of tyrosine kinase receptors arc related to the oncogenesis and progression of several tumors, including lung cancer. Therefore, authors have used sunitinib to treat non-small cell lung cancer (NSCLC) using sunitinib-only regimens, continuous daily doses, or combination chemotherapy (with docetaxel or gemcitabine plus cisplatin), with a definite curative effect in NSCLC clinical trials. Trials involving combined therapy using sunitinib with gemcitabinc and cisplatin for advanced NSCLC have shown that the maxinum tolerated dose is as follows: intermittent oral sunitinib 37.5 mg/d once a day, (Schedule 2/1, i.e., 1 week withdrawal after a 2-week administration) with intravenous infusions of gemcitabine (1,000 mg/m2 on days 1 and 8) and cisplatin (80 mg/m2 on day 1),
舒尼替尼治疗非小细胞肺癌的现状
